Fig. 1: Optimized srRNA vaccines against influenza elicit protective immune responses at ultra-low doses in mice. | Nature Communications

Fig. 1: Optimized srRNA vaccines against influenza elicit protective immune responses at ultra-low doses in mice.

From: Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers

Fig. 1

A Humoral responses as measured by ELISA for anti-hemagglutinin H5 total IgG antibody titers and H1 endpoint IgG antibody titers, 14 days following one or two doses of srRNA/LNP vaccines (n = 5 mice per bar). B Neutralizing antibodies were measured by Hemagglutination Inhibition (HI) assay against H5 and H1, using A/Vietnam/1203/04 and A/California/07/09, respectively, 14 days following one or two doses of srRNA/LNP vaccines (n = 5 mice per bar). Line refers to WHO Correlate of Protection (CoP) threshold. C Splenic T cell responses against H5 and H1 HA, assayed by ELISpot, 14 days following two vaccinations. Symbols represent individual animals (n = 5 mice per bar). Bars represent geometric mean and error bars show 95% CI. Statistical significance was determined by using Mann–Whitney tests vs Saline (black lines) or Kruskal–Wallis test vs 10 ng dose group (blue lines), where *p = 0.0476 (HI assay) and *p = 0.0159 (ELISpot), **p = 0.0079, ***p < 0.0005, ****p < 0.0001.

Back to article page